CO2020001927A2 - Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3 - Google Patents

Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3

Info

Publication number
CO2020001927A2
CO2020001927A2 CONC2020/0001927A CO2020001927A CO2020001927A2 CO 2020001927 A2 CO2020001927 A2 CO 2020001927A2 CO 2020001927 A CO2020001927 A CO 2020001927A CO 2020001927 A2 CO2020001927 A2 CO 2020001927A2
Authority
CO
Colombia
Prior art keywords
immunogenic
pharmaceutical compositions
delta5nsp3
production method
chikungunya virus
Prior art date
Application number
CONC2020/0001927A
Other languages
English (en)
Inventor
Andrea Fritzer
Andreas Meinke
Urban Lundberg
Mario Nebenführ
Jürgen Heindl-Wruss
Robert Schlegl
Arnaud Leon
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of CO2020001927A2 publication Critical patent/CO2020001927A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un proceso para producir un virus de Chikungunya atenuado vivo, inmunogénico, así como también composiciones farmacéuticas que comprenden el mismo.
CONC2020/0001927A 2017-09-21 2020-02-21 Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3 CO2020001927A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192374 2017-09-21
PCT/EP2018/075392 WO2019057793A1 (en) 2017-09-21 2018-09-19 PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3

Publications (1)

Publication Number Publication Date
CO2020001927A2 true CO2020001927A2 (es) 2020-04-01

Family

ID=59955395

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001927A CO2020001927A2 (es) 2017-09-21 2020-02-21 Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3

Country Status (16)

Country Link
US (3) US11484587B2 (es)
EP (1) EP3684404A1 (es)
JP (2) JP7301811B2 (es)
KR (1) KR20200056982A (es)
CN (1) CN111263642A (es)
AR (1) AR113257A1 (es)
AU (1) AU2018337681A1 (es)
BR (1) BR112020003470B1 (es)
CA (1) CA3073234A1 (es)
CO (1) CO2020001927A2 (es)
CR (1) CR20200082A (es)
NZ (1) NZ761619A (es)
PH (1) PH12020500329A1 (es)
SG (1) SG11202001161YA (es)
TW (1) TWI803521B (es)
WO (1) WO2019057793A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3393510T3 (da) 2015-12-23 2023-03-13 Valneva Austria Gmbh Zikavirusvaccine
CA3073234A1 (en) * 2017-09-21 2019-03-28 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
KR20220044734A (ko) 2019-08-09 2022-04-11 발네바 에스이 단일 샷 치쿤구니야 바이러스 백신
US20220288185A1 (en) 2019-08-09 2022-09-15 Valneva Se Chikungunya vaccine formulations
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Sars-cov-2 virus vaccine with adjuvant cytidine-phosphoguanosine
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021191688A1 (en) * 2020-03-27 2021-09-30 Institut Pasteur Defective interfering viral genomes
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309650B1 (en) 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
WO2002089840A1 (en) 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof
CA2545597A1 (en) * 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
JP5744719B2 (ja) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
EP3613761A1 (en) 2008-11-26 2020-02-26 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
US20140050754A1 (en) * 2010-12-10 2014-02-20 National Healthcare Group Pte Ltd Immunogenic chikungunya virus peptides
US9844588B2 (en) * 2011-06-17 2017-12-19 Bharat Biotech International Limited Inactivated chikungunya viruses (CHIKV) comprising an E1-K211E mutation
DK3106176T3 (en) 2011-12-06 2018-01-08 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
DK3393510T3 (da) 2015-12-23 2023-03-13 Valneva Austria Gmbh Zikavirusvaccine
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
CA3073234A1 (en) 2017-09-21 2019-03-28 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3

Also Published As

Publication number Publication date
JP7301811B2 (ja) 2023-07-03
TWI803521B (zh) 2023-06-01
AU2018337681A1 (en) 2020-02-27
BR112020003470A2 (pt) 2020-10-27
CR20200082A (es) 2020-05-17
CN111263642A (zh) 2020-06-09
JP2023116780A (ja) 2023-08-22
US20220016230A1 (en) 2022-01-20
BR112020003470B1 (pt) 2023-09-26
PH12020500329A1 (en) 2020-10-05
AR113257A1 (es) 2020-03-11
US20210322534A1 (en) 2021-10-21
CA3073234A1 (en) 2019-03-28
WO2019057793A1 (en) 2019-03-28
SG11202001161YA (en) 2020-03-30
TW201920663A (zh) 2019-06-01
EP3684404A1 (en) 2020-07-29
US11357846B2 (en) 2022-06-14
NZ761619A (en) 2024-03-22
US20230293661A1 (en) 2023-09-21
JP2020534256A (ja) 2020-11-26
KR20200056982A (ko) 2020-05-25
US11484587B2 (en) 2022-11-01

Similar Documents

Publication Publication Date Title
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
BR112016015496A2 (pt) composição e processo para a produção da composição
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
BR112018071060A2 (pt) produção de monômeros de lignina durante a despolimerização de uma composição contendo lignocelulose
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
BR112017024676A2 (pt) ?métodos para produzir biohidrocarbonetos e mistura de biohidrocarbonetos?
EA201992873A1 (ru) Получение фосфатных производных
BR112017024691A2 (pt) ?métodos para produzir biohidrocarbonetos e para produzir um polímero e mistura de biohidrocarbonetos?
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
BR112016025024A2 (pt) ?processo para preparar compostos ceto, e, uso de farnesil acetona?
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CY1124164T1 (el) Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
BR112016030604B8 (pt) Processo para preparação de ácidos 3- hidroxipicolínicos
PE20151879A1 (es) Proceso para la fabricacion de productos a partir de fibra de madera acetilada
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
CO2017010018A2 (es) Derivados de ácido (s)-2’-vinil-abscísico
BR112018071176A2 (pt) método rápido de produção de vacinas vivas atenuadas